BCDA News and Press, BioCardia Inc. From 11/01/23

SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for t...

2023-10-20 12:43:32 ET More on BioCardia BioCardia doesn't see Phase 3 study meeting primary endpoint, stock slides BioCardia plummets 47% on phase 3 enrollment pause for heart failure therapy Seeking Alpha’s Quant Rating on BioCardia Historical earnin...

SUNNYVALE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces completion of enrollment in its CardiAMP Heart Failure Trial and i...

SUNNYVALE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced a clarification and next steps on its autologous CardiAMP cell th...

2023-09-05 10:36:53 ET Shares of BioCardia ( NASDAQ: BCDA ) tumbled 22% in early trading Tuesday after the biotech company said it doesn’t expect a Phase III pivotal study for its CardiAMP cell therapy to meet its primary endpoint in the treatment of heart failure. BioCar...

SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced it has finalized external review of interim data and evaluated in...

2023-08-09 17:45:25 ET BioCardia, Inc. (BCDA) Q2 2023 Earnings Conference Call August 09, 2023 04:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President & Chief Executive Officer David McClung - Chief Financial Officer ...

2023-08-09 16:22:13 ET BioCardia press release ( NASDAQ: BCDA ): Q2 GAAP EPS of -$0.17. Revenue of $43M (-95.6% Y/Y). For further details see: BioCardia GAAP EPS of -$0.17, revenue of $43M

SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2023 and filed its quarterly report ...

SUNNYVALE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and six months ended J...